Amy W. Hsu

Statistics

Publications

Citations

547

H-Index

Active since

2013

Affiliations

Five Prime Therapeutics (United States)(Current)

Amy W. Hsu is an author at Five Prime Therapeutics (United States) specializing in targeted cancer therapy, molecular oncology, and signal transduction.

Publications per year

2013–2021

Publications

Receptor-type Protein-tyrosine Phosphatase ζ Is a Functional Receptor for Interleukin-34

Sayan Nandi, Mario Cioce, Yee-Guide Yeung et al. · Journal of Biological Chemistry · 2013 · 171 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

Jikui Guan, Ganesh Umapathy, Yasuo Yamazaki et al. · eLife · 2015 · 145 citations · Full text

Veterinary Medicine, Cancer Biology, Oncology +16

Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

Thomas C. Harding, Li Long, Servando Palencia et al. · Science Translational Medicine · 2013 · 120 citations

Medicine, Oncology, Pharmacology +10

Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome

Hongbing Zhang, Lily Pao, Aileen J. Zhou et al. · Proceedings of the National Academy of Sciences · 2014 · 63 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Hong Xiang, Abigael G. Chan, Ago Ahene et al. · mAbs · 2021 · 48 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 5